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Key points:  
-the sphingosine-1-phosphate receptor 2 (S1PR2) is a novel tumor suppressor and survival 
prognosticator in the ABC subtype of DLBCL  
-S1PR2 is a direct, repressed FOXP1 target; ectopic S1PR2 expression induces apoptosis in 
DLBCL cells in vitro and prevents tumor growth  
 
Abbreviations: ChIP, chromatin immunoprecipitation; DLBCL, diffuse large B-cell 
lymphoma; FOXP1, forkhead box protein 1; MALT, mucosa-associated lymphoid tissue; 
MCL, mantle cell lymphoma; MZL, marginal zone lymphoma.  
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Abstract 
Aberrant expression of the oncogenic transcription factor FOXP1 is a common feature of 
diffuse large B-cell lymphoma (DLBCL). We have combined chromatin immunoprecipitation 
and gene expression profiling after FOXP1 depletion with functional screening to identify 
targets of FOXP1 contributing to tumor cell survival. We find that the sphingosine-1-
phosphate receptor 2 (S1PR2) is repressed by FOXP1 in activated B-cell (ABC) and germinal 
center B-cell (GCB) DLBCL cell lines with aberrantly high FOXP1 levels; S1PR2 expression 
is further inversely correlated with FOXP1 expression in three patient cohorts. Ectopic 
expression of wild type S1PR2, but not of a point mutant incapable of activating downstream 
signaling pathways, induces apoptosis in DLBCL cells and restricts tumor growth in 
subcutaneous and orthotopic models of the disease. The pro-apoptotic effects of S1PR2 are 
phenocopied by ectopic expression of the small G-protein Gα13, but are independent of AKT 
signaling. We further show that low S1PR2 expression is a strong negative prognosticator of 
patient survival, alone and especially in combination with high FOXP1 expression. The 
S1PR2 locus has previously been demonstrated to be recurrently mutated in GCB DLBCL; 
the transcriptional silencing of S1PR2 by FOXP1 represents an alternative mechanism leading 
to inactivation of this important hematopoietic tumor suppressor.  
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Introduction 
The forkhead box protein 1 (FOXP1) transcription factor is aberrantly expressed in the 
activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) and 
represents a widely accepted biomarker for survival prognostication in DLBCL. The FOXP1 
genomic locus is recurrently targeted by genomic rearrangements in ABC DLBCL as well as 
in marginal zone lymphoma (MZL) of mucosa-associated lymphoid tissue (MALT) and in 
chronic lymphocytic leukemia, which correlates with a poor prognosis in each disease entity.1-
3
 Primary FOXP1 translocations predominantly involve the immunoglobulin heavy chain 
(IGH) locus, leading to overexpression of the full-length protein;3 in contrast, the rare non-IG 
rearrangements of FOXP1 generate N-truncated isoforms that are believed to drive disease 
progression rather than initiation.4 Most FOXP1-expressing lymphomas exhibit no apparent 
structural aberrations of the gene;5 the short, putatively oncogenic isoforms in particular are 
highly expressed from the wild type locus in ABC DLBCL as a consequence of „normal“ B-
cell activation.6 We have shown earlier that aberrant FOXP1 expression in ABC DLBCL may 
alternatively also result from dysregulated post-transcriptional regulation.7,8 FOXP1 protein 
levels are regulated by the microRNA miR-34a, which itself is either transcriptionally or 
epigenetically silenced in nodal and extranodal DLBCL.7 Therefore, aberrant FOXP1 
expression is a common feature of various types of mature B-cell lymphomas that can result 
from either genetic abnormalities or transcriptional or post-transcriptional dysregulation. 
FOXP1 expression is a well-documented negative prognostic factor in ABC DLBCL and 
MZL that can be used either alone5,9-12 or as part of a biomarker panel.13,14 The inferior 
outcome in patients with FOXP1-expressing DLBCL holds true irrespective of gains or 
structural aberrations at the FOXP1 genomic locus (3p14.1),5 and for patients treated with 
CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone), alone or in 
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combination with rituximab (R-CHOP).5,11,12,15 Due to its robust clinical implications, the 
biology of aberrant FOXP1 expression has received increasing attention lately. The 
elucidation of FOXP1 target genes whose gene products may mediate the effects of FOXP1 
overexpression, and the identification of potentially druggable FOXP1 target pathways is of 
particular interest. FOXP1 is required for normal B-cell development, first during the pro-B to 
pre-B cell transition where it controls VDJ recombination by regulating RAG recombinases16 
and again in the mature B-cell, where it regulates the transition from resting, naive follicular 
B-cell to activated germinal center (GC) B-cell.17 Several recent reports have addressed 
FOXP1 target genes in lymphoma, particularly ABC DLBCL. One study showed that 
FOXP1-mediated repression of its direct target Huntingtin-interacting protein 1-related 
(HIP1R) is associated with poor survival of ABC DLBCL patients.18 Another study 
demonstrated that FOXP1 suppresses apoptosis of DLBCL cells by transcriptional repression 
of a set of pro-apoptotic target genes, which includes the BH3-only protein BIK and several 
p53 regulatory proteins.19 Here, we have combined a genome-wide search for direct FOXP1 
targets using chromatin immunoprecipitation followed by next generation sequencing and 
RNA interference with functional screening for biologically relevant target genes to identify 
novel tumor suppressor proteins in FOXP1-positive DLBCL. We provide evidence that the 
repressed FOXP1 target sphingosine 1-phosphate receptor 2 (S1PR2) has robust tumor 
suppressive activity in DLBCL cells in vitro and in vivo and represents an excellent 
prognostic biomarker that, either alone or in combination with FOXP1 expression, accurately 
predicts survival of ABC DLBCL patients.  
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Methods 
Cell lines and cell culture-based assays 
The DLBCL cell lines used were SU-DHL4, SU-DHL6, SU-DHL10, SU-DHL16 and RC-K8 
of GCB DLBCL subtype and U-2932, OCI-LY3, OCI-LY10, SU-DHL2, SU-DHL5 and 
RIVA of ABC DLBCL subtype (see supplemental methods for a table listing cell line details). 
Cell lines were maintained at 37°C, 5% CO2 in a humidified atmosphere in RPMI or IMDM 
(RIVA, OCI-LY10) supplemented with 10% (OCI-LY10, RIVA, SU-DHL2 and SU-DHL5) 
or 20% heat-inactivated FBS and antibiotics. The AKT inhibitor MK-2206 (Selleckchem) was 
dissolved in dimethyl sulfoxide. For RNA interference experiments, 1x106 DLBCL cells were 
nucleoporated with 100nM of siRNA using the Amaxa Nucleofector II device. Knock-down 
efficiency was confirmed 24h after nucleoporation by real-time qPCR. The siRNAs were 
obtained from Qiagen with the following target sequences for FOXP1.1 
(CAGGCGGTACTCAGACAAATA), FOXP1.2 (CAGCAGCAAGTTAGTGGATTA), 
GNA12 (CCGGATCGGCCAGCTGAATTA), GNA13 (CACTATCATTGTATCCATATA), 
ARHGEF1 (CAACGTCGCCTTTGAA CTTGA). Allstars negative control siRNA (Qiagen) 
was used as control. For the purpose of ectopic gene expression, 1x106 DLBCL cells were 
nucleoporated with 3µg of plasmid DNA using the Amaxa Nucleofector II device. Cells were 
harvested 48h post transfection for protein extraction or subjected to functional analysis., 
CellTiter-Blue reagent (Promega) was used for viability assessment. The quantification of 
apoptosis by Annexin V detection kit (BD Pharmingen) or cleaved Caspase-3 (Biovision) was 
performed according to the manufacturer’s instructions. Flow cytometry was performed on a 
Cyan ADP 9 instrument (Beckman Coulter) and analyzed using FlowJo software. Protocols 
for qRT-PCR, Western blotting, RNA and ChIP sequencing, as well as inducible protein 
expression and site-directed mutagenesis are available in the supplemental methods. All 
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animal experimentation was approved by the Zürich Cantonal Veterinary Office (licenses 
147/2011 and 224/2014 to A.M.) and is described in the supplemental methods. 
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Results 
The hematopoietic oncoprotein FOXP1 promotes cell survival and functions as a 
transcriptional repressor in DLBCL 
In this study, we have embarked on a global survey of genes that are (1) regulated by FOXP1 
at the transcriptional level, (2) are directly bound by FOXP1 as determined by chromatin 
immunoprecipitation, and (3) affect proliferation and survival in cell culture models of 
DLBCL. We selected several cell lines for experimentation based on their FOXP1 expression; 
as noted previously by us and others, the strong expression of one or several FOXP1 isoforms 
was more commonly observed in ABC- compared to GCB-derived cell lines (supplemental 
Figure 1A-C).  To identify genes that are controlled by FOXP1, we silenced its expression in 
the FOXP1-positive DLBCL cell lines SU-DHL6, U-2932 and RIVA by electroporation with 
siRNAs targeting either all (siFOXP1.1) or preferentially the high molecular weight 
(siFOXP1.2) isoforms. FOXP1 knock-down was efficient in all three cell lines (Figure 1A, 
supplemental Figure 1D,E), reduced tumor cell viability as determined by metabolic activity 
assay (Figure 1B-D), and induced apoptosis as assessed by flow cytometric analysis of 
Annexin V and active caspase-3 (Figure 1E-J, supplemental Figure 1F,G); in contrast, the 
FOXP1-negative cell line RC-K8 did not undergo cell death upon electroporation with the 
same siRNAs, arguing against potential off-target effects (supplemental Figure 1H,I). The 
siRNA targeting all isoforms was generally more potent at inducing cell death than the siRNA 
that preferentially targets the high molecular weight isoforms (Figure 1B-J). Silencing of 
FOXP1 in FOXP1-positive cell lines further consistently dysregulated the expression (>2 
fold) of 103 genes in SU-DHL6 and 66 genes in U-2932 cells as determined by RNA 
sequencing (supplemental Table 1). To examine which of the FOXP1-regulated genes are 
direct targets of the transcription factor, we performed chromatin immunoprecipitation (ChIP) 
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with a FOXP1-specific antibody of the two FOXP1hi (U-2932 and SU-DHL6) cell lines also 
used for transcriptional profiling, as well as one FOXP1lo (SU-DHL4) and one FOXP1-
negative (RC-K8) cell line (Figure 1K). ChIP was followed by Illumina sequencing of the 
precipitated genomic DNA. The consensus sequence of FOXP1-bound regulatory regions that 
we identified by this approach was identical in both FOXP1hi cell lines (Figure 1L) and very 
similar to a previously reported sequence.20 FOXP1-bound regulatory regions were 
predominantly identified at transcription start sites (data not shown). Of all ~6000 genomic 
loci bound by FOXP1 (supplemental Table 2), roughly one third were shared by the two 
examined FOXP1hi cell lines (U-2932 and SU-DHL6, Figure 1M). The ChIP-derived 
information on FOXP1-bound loci was then integrated with the lists of differentially 
expressed genes. Of 430 genes that were dysregulated upon FOXP1-specific RNAi  as 
determined by RNA sequencing and/or directly bound by FOXP1 as determined by ChIP-
sequencing (see the supplemental methods for a detailed description of criteria and cut-offs), 
27 were selected for functional analysis because they had previously been mentioned in the 
literature in the context of cancer, tumor suppression or B-cell biology. Figure 1N shows the 
gene expression changes upon FOXP1 knock-down in the two cell lines as well as the fold 
enrichment and number of binding sites identified in FOXP1 chromatin-immunoprecipitated 
DNA of the 27 genes. We conclude from the combined results that FOXP1 promotes cell 
survival in DLBCL cell lines and regulates the expression of numerous target genes by 
binding to highly conserved regulatory regions. 
 
Expression of the sphingosine-1-phosphate receptor S1PR2 is inversely correlated with 
FOXP1 expression in patient biopsies 
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We next proceeded to functionally examine the 27 identified FOXP1 targets by manipulating 
their expression in U-2932 cells. FOXP1 predominantly serves as a transcriptional repressor 
rather than an activator of target gene expression; accordingly, we identified only two 
transcripts whose expression decreased upon FOXP1 knock-down. siRNAs specific for these 
positively regulated genes failed to affect cell viability or apoptosis (supplemental Figure 
2A,B); in contrast, ten of the 25 repressed FOXP1 target genes reduced the viability of U-
2932 cells by >50% upon ectopic expression, i.e. in a gain-of-function screen (Figure 2A). 
This loss of viability coincided with apoptosis induction in U-2932 cells (Figure 2B), 
suggesting that the ten genes function as potential tumor suppressors in DLBCL. 
To determine which of the identified pro-apoptotic FOXP1 targets exhibit expression patterns 
that are inversely associated with the expression of FOXP1 in patient biopsies, we took 
advantage of publicly accessible gene expression profiling (GEP) datasets. One of the two 
available GEP datasets included 496 DLBCL patients that had been recruited as part of the 
International DLBCL Rituximab-CHOP Consortium Program Study14,21,22 and received R-
CHOP therapy; the other cohort consisted of 350 patients enrolled in the 
Lymphoma/Leukemia Molecular Profiling Project, respectively, that had been treated with 
either CHOP or R-CHOP.23 We were able to confirm earlier observations demonstrating that 
FOXP1 expression is consistently higher in ABC compared to GCB DLBCL cases in both 
datasets (Figure 2C-F). To our surprise, only a few of the 10 repressed targets with pro-
apoptotic activity identified in the combined approaches outlined above were correlated 
inversely with FOXP1 in terms of their transcript abundance (supplemental Figure 2C-K); 
however, one candidate, the sphingosine-1-phosphate receptor 2 (S1PR2), exhibited a nearly 
perfect and highly significant inverse association with FOXP1 in both DLBCL cohorts 
(Figure 2C-F). A similar inverse expression pattern was observed also in the subset of ABC-
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DLBCL-derived cell lines that we had at our disposal (Figure 2G). During B-cell ontogeny, 
FOXP1 is highly expressed in the naive B-cell, and then again in memory B-cells as judged 
based on publicly available gene expression profiles;24 both phases of B-cell development are 
characterized by low S1PR2 expression (Figure 2H). In contrast, FOXP1lo centrocytes and 
centroblasts exhibit de-repressed S1PR2 expression (Figure 2H). The combined functional 
and gene expression data support the conclusion that S1PR2 is repressed at the transcriptional 
level in DLBCL due to aberrant expression of its negative regulator FOXP1 and that the 
dysregulation of S1PR2 may contribute to the survival of DLBCL cells. 
 
S1PR2 is a direct repressed target of FOXP1 with pro-apoptotic activity in DLBCL cell 
lines 
To validate and extend our findings linking FOXP1 to S1PR2 regulation using additional cell 
lines and approaches, we silenced FOXP1 expression in the three before-mentioned FOXP1-
positive cell lines as well as the FOXP1-negative cell line RC-K8. Silencing of FOXP1 
expression with the siRNA targeting all isoforms (siFOXP1.1) lead to an increase in the 
expression of S1PR2 by a factor of 2-4 fold as determined by qRT-PCR in the three FOXP1- 
positive cell lines, but not the  FOXP1-negative cell line (Figure 3A-D). We next sought to 
confirm the ChIP-seq results by ChIP followed by qPCR (ChIP-qPCR) specific for the S1PR2 
regulatory region that is bound by FOXP1. The ChIP-seq had identified two regions 2.5 and 
5kb upstream of the S1PR2 transcription start site (designated „A“ and „B“, supplemental 
Figure 3) to be highly enriched in chromatin immunoprecipitates generated with a FOXP1-
specific relative to an irrelevant antibody. This observation could be confirmed by ChIP-
qPCR in four examined FOXP1-positive cell lines (Figure 3E-H); no PCR product was 
obtained in immunoprecipitates from FOXP1-negative RC-K8 cells (data not shown). In 
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general, the region 5kb upstream of the transcription start site („B“) was more robustly bound 
by FOXP1 (and therefore amplified by qPCR), whereas FOXP1 binding to the region 2.5kb 
upstream („A“) was more variable across cell lines and experiments (Figure 3E-H). Finally, 
we restored S1PR2 expression in three cell lines that are amenable to genetic manipulation 
with cDNA expression constructs (one FOXP1hi, one FOXP1lo and one FOXP1-) and 
determined the effects of this treatment on tumor cell viability and apoptosis. Ectopic S1PR2 
expression was approximately in the same range as S1PR2 expression resulting from FOXP1 
depletion by RNAi (as assessed by qRT-PCR, data not shown), and consistently reduced the 
survival of all examined cell lines (Figure 3I). The loss of viability correlated well with 
induction of apoptosis as evidenced by staining for Annexin V and active caspase-3 (Figure 
3J,K). We next used lentiviral transduction to generate SU-DHL6 cells harboring the S1PR2 
gene under doxycyclin control, in which GFP expression allows for tracking of successful 
transduction. GFP-positive cells were sorted to >90% purity (Figure 3L); the addition of 
doxycyclin induced S1PR2 expression in GFP-positive, but not GFP-negative cells (Figure 
3M) and strongly reduced cell survival (Figure 3N), which could be attributed to apoptosis 
induction (Figure 3O). In summary, S1PR2 is a directly regulated, repressed target of FOXP1 
in DLBCL cell lines that exhibits robust pro-apoptotic activity; the results suggest that the 
loss of S1PR2 expression likely confers a survival advantage to DLBCL cells due to 
protection from apoptosis.  
 
S1PR2 signals via the small G-protein Gα13 to induce apoptosis 
S1PR2 is a G protein-coupled receptor which binds the lipid signaling molecule sphingosine 
1-phosphate and couples to either of two small G-proteins, Gα12 or Gα13 (encoded by 
GNA12 and GNA13, respectively), to activate  downstream signaling events.25 Both small G-
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proteins are predominantly known for their activity in regulating proliferation and migration. 
To assess whether Gα12 and/or Gα13 contribute to pro-apoptotic S1PR2 signaling, we first 
constructed a point mutant, S1PR2 R147C, which is expressed at normal levels but lacks the 
ability to interact with both small G-proteins.26 The pro-apoptotic activity of S1PR2 R147C 
was reduced relative to wild type S1PR2 in several cell lines, as determined by cell viability 
assay as well as Annexin V and active caspase-3 staining (Figure 4A-I). Interestingly, the 
ectopic expression of either of the two small G-proteins phenocopied the effects of S1PR2 on 
viability and cell death (Figure 4A-I). We next assessed whether either or both small G-
proteins are required for S1PR2-driven cell death in SU-DHL6 cells harboring the S1PR2 
gene under doxycyclin control; interestingly, the siRNA-mediated knock-down of Gα13, but 
not of Gα12, reversed the phenotype of inducible S1PR2 expression (Figure 4J,K). The 
silencing of ARHGEF, a Rho guanine nucleotide exchange factor (GEF) known to function 
downstream of both small G-proteins to activate RhoA by exchanging bound GDP for GTP, 
showed similar trends as Gα13 depletion, which were however not statistically significant 
(Figure 4J,K). All three siRNAs led to a depletion of their target mRNAs by 50% or more and 
corresponding protein by approximately 50% (supplemental Figure 4A,B). The combined 
results indicate that, although both Gα12 and Gα13 can in principle transmit pro-apoptotic 
signals downstream of S1PR2, only Gα13 is active in the examined DLBCL cell line. This 
observation is consistent with Gα13, but not Gα12, co-expression with S1PR2 in centrocytes 
and centroblasts (Figure 2H, Figure 4L).  
As S1PR2 signaling has been shown to inhibit AKT phosphorylation and AKT-driven 
migration,26 we speculated that S1PR2 signaling might impair DLBCL cell survival by 
preventing AKT-mediated survival signaling. However, we found no evidence for a role of 
AKT in S1PR2-driven cell death, as AKT activity -as determined by its phosphorylation on 
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serine 473- did not change consistently upon FOXP1 knock-down  (Figure 5A, supplemental 
Figure 5A) or ectopic S1PR2 or Gα12/13 expression (Figure 5B, supplemental Figure 5B-D) 
and a constitutively active, myristoylated form of AKT did not reverse the consequences of 
S1PR2 overexpression in DLBCL cell lines (Figure 5C). Furthermore, an inhibitor of AKT 
signaling had only modest effects on the viability of DLBCL cell lines at concentrations that 
strongly reduced AKT autophosphorylation on serine 473, and the susceptibility of individual 
cell lines did not correlate with their steady state AKT activity (which is high in U-2932 and 
low in SU-DHL6 cells; Figure 5D, supplemental Figure 5E,F). The combined results suggest 
that the survival-promoting effects of FOXP1 depend on the repression of its target S1PR2 
and of downstream pro-apoptotic signaling via the small G-protein Gα13, but not on AKT-
driven survival signaling. 
 
S1PR2 is a bone fide tumor suppressor in DLBCL in vivo 
To examine whether the inducible expression of S1PR2 kills DLBCL cells in vivo,  we 
subcutaneously implanted either 10x106 GFP-positive (>95% pure, data not shown) or –
negative SU-DHL6 cells into NSG mice, allowed palpable tumors to form, and induced 
transgene expression by administration of doxycyclin via the chow. S1PR2 expression could 
be verified in GFP-positive cells from doxycyclin recipients, but not the other two groups 
(Figure 6A); interestingly, S1PR2 expression strongly delayed tumor outgrowth in the 
majority of animals, as evidenced by the tumor volume and weight over time and at the study 
endpoint (Figure 6B-E). Interestingly, GFP-negative cells outcompeted GFP-positive (S1PR2-
expressing) cells in all examined tumors exposed to doxycyclin (Figure 6F), despite the fact 
that this population constituted less than 5% of the overall population at the time of 
transplantation.  
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We next established an orthotopic/systemic model of DLBCL by subcutaneously passaging 
GFP-positive and –negative SU-DHL6 cells prior to their ex vivo expansion and intravenous 
injection into NSG mice. Cell populations were ~95% pure at injection (data not shown). 
Doxycyclin was administered to one half of the recipients of GFP-positive cells and all GFP-
negative cell recipients once tumor cells appeared in the circulation after 15 days of 
engraftment, as judged by positive staining for the human-specific leukocyte marker CD45 
(data not shown). Whereas the recipients of GFP-negative cells and the recipients of GFP-
positive cells not fed doxycyclin began to lose weight at 17 days post engraftment, the weight 
of GFP-positive cell recipients remained relatively stable until the study endpoint (20 days 
post engraftment; Figure 6G,H). The overall tumor burden in both spleen and blood was 
highest in recipients of GFP-negative cells, and similar in recipients of GFP-positive cells 
irrespective of doxycyclin exposure (Figure 6I-K). However, as in the xenograft model, GFP-
negative (doxycyclin-unresponsive) cells outcompeted GFP-positive cells in all mice on 
doxycyclin relative to mice not under selective pressure, increasing from only 5% of the 
tumor cell population at the time of injection to >30% of the population in blood and spleen at 
the study endpoint (Figure 6L,M). The combined results confirm that S1PR2 acts as a bona 
fide tumor suppressor in DLBCL in vivo in both subcutanous and orthotopic models of the 
disease, and delays or restricts tumor cell outgrowth upon inducible expression.  
To confirm the tumor suppressor function of S1PR2 in another model, we generated mice that 
are either wild type or harbor a heterozygous deletion of the S1PR2 gene and express MYC 
under the control of the immunoglobulin heavy chain enhancer (Emu-MYC). Interestingly, the 
loss of only one S1PR2 allele was sufficient to significantly accelerate the formation of MYC-
driven nodal B-cell lymphomas (Figure 6N); once MYC+S1PR2+/- tumors had formed (in the 
spleen and various lymph nodes, especially cervical, mediastinal, brachial and inguinal) they 
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grew with similar kinetics as MYC+S1PR2+/+ tumors and were morphologically 
indistinguishable (data not shown). This model thus provides another piece of evidence for 
the tumor suppressive properties of S1PR2 in B-cells, and suggests that the loss of S1PR2 
function is an early event in DLBC lymphomagenesis. 
 
S1PR2 is a positive prognostic marker in DLBCL patients 
To assess a possible prognostic value of S1PR2 expression, alone and in combination with 
FOXP1 expression, we examined S1PR2 and FOXP1 transcript levels in 470 patients on R-
CHOP therapy of the International DLBCL Rituximab-CHOP Consortium Program Study14 
and the 181 and 233 patients on CHOP and R-CHOP therapy, respectively, of the 
Lymphoma/Leukemia Molecular Profiling Project23 in relation to their overall survival. High 
expression of FOXP1 was associated with inferior survival in all three cohorts, although the 
difference was not statistically significant in all cases (Figure 7A-C). Interestingly, high 
expression of S1PR2, which is inversely correlated with FOXP1 expression in all three 
cohorts as shown earlier (Figure 2), was a clear prognosticator of superior survival, alone and 
especially in combination with low FOXP1 expression (Figure 7D-F and Figure 7G,H, 
respectively), and predominantly in the ABC subtype of DLBCL (data not shown). The 
likelihood of survival was particularly dismal in patients with FOXP1hiS1PR2lo tumors, and 
especially favorable in FOXP1loS1PR2hi cases, and high S1PR2 expression even allowed for 
accurate survival prognostication of FOXPhi cases (Figure 7G,H). Overall, the beneficial 
effect of S1PR2 expression on patient survival is consistent with its strong pro-apoptotic 
properties in DLBCL cell lines, and provides an explanation for the robust survival advantage 
of DBLCL cells that is associated with FOXP1-mediated S1PR2 repression.  
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Discussion 
In this study, we have combined ChIP-sequencing and RNA sequencing with the functional 
analysis of individual target genes to identify novel FOXP1-regulated tumor suppressors in 
DLBCL. We found all our DLBCL cell lines to depend heavily on FOXP1 expression for 
growth and survival, irrespective of whether they were of ABC or GCB subtype. Consistent 
with a previous report,6 we found the shorter isoforms of FOXP1 to be somewhat more 
critical to cell survival than the full length isoforms, although our siRNAs were not entirely 
specific for either one or the other. Of the 27 direct FOXP1 targets uncovered by our 
integrative approach, ten exhibited pro-apoptotic activity upon ectopic expression and 
therefore represent candidates whose repression by FOXP1 is likely to contribute to FOXP1-
driven tumor cell survival. We focused on the repressed target S1PR2, a G-protein coupled 
receptor (GPCR), because its expression was strongly negatively correlated with FOXP1 
expression in two large DLBCL patient cohorts. S1PR2 could be validated as a bona fide 
target of FOXP1 with strong pro-apoptotic activity in multiple cell lines. Ectopic expression 
of wild type S1PR2 kills cells of both DLBCL subtypes with equal efficiency, suggesting that 
loss of S1PR2 expression is a critical pathogenetic event in both GCB as well as ABC 
DLBCL. Indeed, the loss of S1PR2 activity in (predominantly FOXP1-negative) GCB 
DLBCL was recently attributed to inactivating point mutations in the S1PR2 coding sequence, 
which either abrogate expression of the protein, or are structurally damaging.26 Interestingly, 
such mutations are almost exclusively found in GCB DLBCL and hardly ever occur in 
(FOXP1-positive) ABC DLBCL.26 Earlier work had already identified numerous somatic 
mutations in the 5‘ untranslated region of S1PR2 in DLBCL, with the location and context of 
the mutations pointing to aberrant somatic hypermutation as the underlying mechanism.27 Our 
data on FOXP1-driven S1PR2 repression imply that the conservation of two wild type S1PR2 
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alleles in ABC DLBCL26 may be due to this alternative, transcriptional mechanism of 
abrogating S1PR2 expression, which should relieve negative selective pressure on the S1PR2 
gene.   
In GCB DLBCL, the critical contribution of S1PR2 has been attributed to its dual role in 
confining germinal center B-cells to lymph nodes and thus preventing their recirculation and 
in growth inhibition; consequently, mice lacking direct downstream effectors of the S1PR2-
regulated signaling pathway, i.e. Gα13 or ARHGEF1, are characterized by the systemic 
dissemination of germinal center B-cells and their seeding and growth in distant organs.26 
Similarly, mice lacking both alleles of S1PR2 exhibit higher frequencies and greater size of 
spontaneously occurring germinal centers, and half of all mice develop B-cell lymphomas of 
GCB morphology and molecular characteristics by 1.5 to 2 years of age.27 Here, we show that 
S1PR2, in addition to its role in GC B-cell confinement and growth inhibition, exerts a direct 
tumor suppressive function in B-cells by promoting tumor cell apoptosis: the ectopic 
expression of S1PR2, either upon electroporation of DLBCL cell lines with cDNA expression 
constructs or upon doxycyclin-driven, inducible transgene expression from a genomic locus, 
rapidly induces tumor B-cell death in vitro and in vivo. Inducible S1PR2 expression alone is 
sufficient to strongly delay tumor development in vivo in a subcutaneous xenograft model. 
Additional results obtained using a novel systemic model of DLBCL engraftment and growth 
in the spleen and blood lend further support to the notion that S1PR2 functions as a general 
pro-apoptotic tumor suppressor in B-cells. Apoptosis induction by S1PR2 involves its 
downstream mediator Gα13, as a mutant incapable of interacting with this small G-protein 
fails to trigger cell death, the ectopic expression of Gα13 (and also of the closely related 
Gα12) phenocopies the effects of ectopic S1PR2 expression, and the depletion of Gα13 
rescues the pro-apoptotic effects of ectopic S1PR2 expression. Whereas the receptor-proximal 
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signaling events via small G-proteins thus promote both germinal center confinement26 and 
tumor cell apoptosis as shown here, we could not find evidence for a role of AKT inhibition 
in S1PR2-driven tumor cell death. Several lines of evidence indicate that, while most DLBCL 
cell lines are modestly sensitive to AKT inhibitors, this may represent an off target effect as 
sensitivity is not correlated with active AKT signaling. Furthermore, the ectopic expression of 
constitutively active, myristoylated AKT fails to rescue DLBCL cells from S1PR2-driven 
apoptosis, as would be expected if AKT-driven signaling were critical to cell survival. In 
conclusion, although the receptor-proximal signaling events, as well as the biological 
consequences of S1PR2 expression on cell survival have now been elucidated in detail, the 
exact mechanism of apoptosis induction remains elusive. More work will be required to 
clarify the link between this GPCR, caspase activation and apoptosis. 
Aside from the implications of the newly identified FOXP1 target genes for DLBCL 
pathogenesis, our findings are also of interest with regard to normal GC B-cell function. We 
propose that the regulation of S1PR2 as well as of activation-induced cytidine deaminase 
(AID) by FOXP1, which we picked up in our ChIP of FOXP1-bound promoters and were able 
to confirm by ChIP-PCR and RNA sequencing after FOXP1 knock-down (data not shown), 
accounts for the negative regulatory effects of FOXP1 on the germinal center reaction. 
FOXP1 downregulation in GC B-cells on the one hand allows for S1PR2 re-expression, GC 
retention and negative selection of GC B-cells, and on the other hand promotes re-expression 
of AID and AID-induced class switching. We propose a model in which the downregulation 
of FOXP1 and subsequent de-repression of S1PR2 and AID promote various key properties of 
GC B-cells such as class switching, the ability to undergo apoptosis and allow for negative 
selection, and confinement to the GC area of the lymph node (see model in supplemental 
Figure 6). In summary, S1PR2 is a biologically relevant target of FOXP1 under physiological 
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conditions as well as in tumor cells with aberrant FOXP1 expression, warranting further 
research into the pathways that are regulated by the FOXP1/S1PR2 signaling axis in health 
and disease states. 
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Figure Legends 
Figure 1. Identification of FOXP1 target genes by ChIP sequencing combined with RNA 
sequencing. (A-J) Either all (siFOXP1.1) or preferentially the high molecular weight 
isoforms (siFOXP1.2) of FOXP1 (isoforms designated FOXP1_8 and 1_6) were depleted in 
the three DLBCL cell lines U-2932, SU-DHL6 and RIVA for 72h prior to the assessment of 
FOXP1 levels, and of cell viability and cell death. An unspecific control siRNA was used for 
comparison. (A) FOXP1 levels as assessed by Western blotting with α-TUBULIN as loading 
control. (B-D) Cell viability as determined by Cell Titer Blue assay. (E-G) Apoptosis as 
determined by Annexin V staining followed by FACS. (H-J) Apoptosis as determined by 
cleaved/active caspase-3 staining followed by FACS. Data in B-J represents means + SEM of 
at least 3 independent experiments per cell line. (K) Western Blot showing FOXP1 expression 
in the four cell lines used for ChIP-Seq with α-TUBULIN as loading control. (L) Top 
enriched motif as identified by DREME in U-2932 (E=4.1e-295) and SU-DHL6 (E=2.1e-486) 
cells. (M) Venn-Diagram showing the overlap of identified ChIP peaks in the three FOXP1-
positive cell lines. (N) 27 FOXP1 targets as identified by RNA-Seq and ChIP-Seq. Log2 
transformed gene expression (counts per million; blue/red color code) of U-2932 and SU-
DHL6 cell lines transfected with the indicated siRNAs is shown alongside the fold enrichment 
of ChIP-peaks in the same cell lines (grey/green color code). *P < .05, ** P < .01, *** P < 
.001, calculated using two-tailed students t-test. 
 
Figure 2. Functional analysis of the pro-apoptotic activity of putative FOXP1 targets. 
(A,B) U-2932 cells were transfected with the indicated expression plasmids and analyzed with 
respect to cell viability and apoptosis 48h later. Cell viability was determined by Cell Titer 
Blue assay (A) and apoptosis was assessed by Annexin V staining (B). Red indicates target 
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genes that reduce cell viability by >50% upon ectopic expression, compared to the empty 
vector control. Data are shown as means of one or two (+ SEM) experiments; note that the 
same batch of transfection reagents was used throughout, every cDNA was expressed under 
the same promotor, and the same batch of transfected cells was used for the Cell Titer Blue 
and apoptosis assays. (C-F) FOXP1 and S1PR2 expression in tumors from two patient cohorts 
consisting of 350 DLBCL patients23 (C,D) and 496 DLBCL patients14 (E,F), that were further 
stratified based on ABC vs. GCB subtype. *** P < .001 calculated using two-tailed Mann-
Whitney U test. Datasets were either analyzed using R software, or using the R2 microarray 
analysis and visualization platform (http://r2.amc.nl). (G) S1PR2 and FOXP1_6 expression 
levels were determined in DLBCL cell lines by qRT-PCR (normalized to ACTIN). Red dots 
indicate ABC-type, green dots GCB-type cell lines. The correlation coefficient was calculated 
for the ABC cell lines only. (H) Expression levels of FOXP1 and S1PR2 during B-cell 
development were determined using publicly available data from Genomicscape.24 The 
number in brackets denotes the number of samples analyzed per B-cell developmental stage. 
  
Figure 3. S1PR2 is a direct, repressed target of FOXP1 with pro-apoptotic activity in 
DLBCL cell lines. (A-D) S1PR2 expression levels were determined by qRT-PCR 
(normalized to ACTIN) after 72h of FOXP1 depletion in the indicated cell lines. Data are 
represented as fold change over the negative control siRNA (means + SEM of at least 3 
independent experiments are shown). (E-H) ChIP followed by qPCR of two FOXP1-bound 
regions 2,5kb and 5kb upstream of the S1PR2 transcription start site that were identified by 
ChIP sequencing. Data are shown as fold enrichment relative to an unspecific IgG control 
antibody for the four indicated cell lines. A locus in the PRR20A gene was used as a negative 
control.17 Data represents means + SEM of at least 3 independent experiments. (I-K) Viability 
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and apoptosis of the three indicated DLBCL cell lines 48h post transfection with an S1PR2 
expression plasmid or empty vector. Cell viability was assessed using Cell Titer Blue (I) and 
apoptosis was assessed using Annexin V (J) or cleaved caspase-3 staining (K). Data represent 
means + SEM of at least 3 independent experiments. (L) A representative eGFP histogram of 
SU-DHL6 cells after infection with virus particles harboring pIND21-S1PR2. (M-O) S1PR2 
expression was induced for 72h with doxycyclin in SU-DHL6 cells transduced with pIND21-
S1PR2 prior to the assessment of S1PR2 transcript levels (M), as well as viability and 
apoptosis by Cell Titer Blue assay and Annexin V staining (N,O); data of 3 independent 
experiments are shown as means + SEM. * P < .05, ** P < .01, *** P < .001 calculated using 
two-tailed students t-test.  
 
Figure 4. The pro-apoptotic activity of S1PR2 is mediated by Gα13. (A-I) The three 
indicated DLBCL cell lines were transfected with plasmids encoding either wild type or 
mutant S1PR2, or Gα12 or Gα13. Cell viability and apoptosis were assessed after 48h by Cell 
Titer Blue assay (A,D,G), Annexin V staining (B,E,H) and cleaved caspase-3 staining (C,F,I). 
Data are represented as means + SEM of at least 3 independent experiments. Note that 
roughly equal expression of the four constructs was verified using FLAG-tagged versions of 
the proteins (data not shown). (J,K) Viability and apoptosis of SU-DHL6 cells that inducibly 
express S1PR2, 72h post transfection with the indicated siRNAs; transfected cells were 
additionally exposed to doxycyclin for the last 48h of the experiment where indicated. Cell 
viability was assessed using Cell Titer Blue assay (J); apoptosis was assessed by V staining 
(K). Data represent means +SEM of 3 independent experiments. * P < .05, ** P < .01, *** P 
< .001 calculated using two-tailed students t-test. (L) Expression levels of Gα12 and Gα13 
during B-cell development, as determined using publicly available data from Genomicscape.24 
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Figure 5. AKT activity is neither affected by FOXP1/S1PR2 signaling nor required for 
DLBCL cell survival. (A,B) AKT activity was assessed by phospho-S473-specific Western 
blotting of the indicated cell lines 72h after transfection with FOXP1-specific or control 
siRNAs (A), or after transfection with the indicated expression plasmids (B). Total AKT and 
α-TUBULIN are shown as loading controls. (C) Cell viability of U-2932 cells was measured 
by Cell Titer Blue assay 48h after transfection with expression plasmids encoding S1PR2 and 
a myristoylated, constitutively active form of AKT. Data were normalized to empty plasmid 
(pTCN) and represent means + SEM of 3 independent experiments. (D) Cell viability of the 
indicated cell lines was measured by Cell Titer Blue assay after 24h of treatment with the 
indicated concentrations of the AKT inhibitor MK-2206 or the vehicle control (DMSO). Data 
were normalized to vehicle control (DMSO) and are represented as means + SEM of 3 
independent experiments.  
 
Figure 6. The inducible expression of S1PR2 delays tumor growth in vivo. (A-F) 
NOD/SCID/IL2Rγ−/− mice were subcutaneously inoculated in both flanks with 1×107 SU-
DHL6 cells that had been transduced with pIND21-S1PR2 and sorted for eGFP. eGFP-
negative cells were used as a negative control. Mice were switched to doxycyclin-containing 
chow once tumors were palpable (on day 13 post transplantation). Mice transplanted with 
eGFP-positive cells were maintained on normal chow as another negative control. The data 
shown were pooled from two independent experiments. (A) S1PR2 expression as determined 
by qRT-PCR (normalized to ACTIN) of resected tumors. (B,C) Tumor volume as determined 
over time (days post transplantation, B; p-values calculated using 2-way ANOVA with Tukey 
multiple comparison test) and at the study endpoint (C). (D) Tumor weight at the study 
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endpoint. (E) Representative excised tumors of the indicated treatment groups. (F) eGFP-
positive fraction of tumor cells at the study endpoint. (G-M) 1×107 subcutaneously passaged 
SU-DHL6 (pIND21-S1PR2) cells were sorted for eGFP expression and injected into the tail 
veins of NOD/SCID/IL2Rγ−/− mice; mice were treated with doxycyclin starting on day 15 
post injection as described in A-F. (G) Body weight per mouse as recorded every three days 
for the three treatment arms (means +/- SEM; p-values calculated using 2-way ANOVA with 
Tukey multiple comparison test). (H) Body weight change relative to day 15 post tumor cell 
injection. (I,J) Spleen weight and tumor cell burden per mg of spleen at the study endpoint. 
(K) Tumor cell burden in the blood at the study endpoint, as determined by CD45 staining. 
(L,M) Fraction of eGFP-positive cells in % of all human CD45-positive tumor cells in the 
spleens (L) and blood (M) of the indicated groups at the study endpoint. Horizontal lines 
indicate the medians, each symbol represents one tumor. * P < .05, ** P < .01, *** P < .001, 
calculated using two-tailed Mann-Whitney U test for all panels except B,G and N. (N) 
Kaplan-Meyer plot of Emu-MYC-transgenic (MYC-tg), S1PR2+/- and S1PR2+/-/MYC-tg mice 
(4 per group). **, P < .01; calculated with Log-rank (Mantel-Cox) test. 
 
Figure 7. S1PR2 expression correlates directly with overall survival in DLBCL patients. 
(A–H) Kaplan–Meier curves displaying overall survival probability of three DLBCL patient 
cohorts (GEO accession nos. GSE31312 and GSE10846) treated either with R-CHOP 
(rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone; 
A,C,D,F,G) or CHOP only (B,E,H) as a function of FOXP1 expression (A-C), S1PR2 
expression (D-F) and FOXP1/S1PR2 expression combined (G,H).  All cohorts were 
subdivided based on low (<median) or high (>median) FOXP1 expression and low (first to 
third quartile) and high (fourth quartile) S1PR2 expression. The log-rank test was used for 
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statistical analysis: *, P < .05; **, P < .01; ***, P < .001. The patient cohorts shown were 
enrolled in the Lymphoma/Leukemia Molecular Profiling Project (A,B,D,E,G,H) and in the  
International DLBCL Rituximab-CHOP Consortium Program Study (C,F). 
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